Repeatability of tumour perfusion measurement with [15O]H2O PET in prostate cancer

Read full text
Authors: Mads Ryø Jochumsen, Jens Christian Sørensen, Nana Louise Christensen, M. Haislund, M.B. Borre, Kirsten Bouchelouche, Lars Poulsen Tolbod
Cited by: 1
References: 30

Abstract

BACKGROUND: Tumour perfusion is a universal cancer biomarker with potential value in characterising primary prostate tumours and longitudinal measurements for evaluation of treatment response. To evaluate whether a change in perfusion is significant, the reproducibility of the measurement must be known. [15O]H2O positron emission tomography (PET) is the gold standard for non-invasive quantitative perfusion imaging, however repeatability data on prostate cancer are currently unavailable. Hence, the aim of the present study is to determine the repeatability of [15O]H2O tumour perfusion in prostate cancer. RESULTS: Thirteen well-defined MRI PI-RADS lesions from ten patients were studied. The repeatability of [15O]H2O K1 was 30% using both parametric image calculation and volume of interest (VOI)-based analysis. Intraclass correlation coefficient (ICC) was 0.89 and 0.91 for parametric image calculation and VOI-based analysis, respectively. A study sample size of 10 patients should be sufficient for detecting a relative change of 20% over time. CONCLUSIONS: [15O]H2O tumour perfusion in localised prostate cancer can be measured with a high repeatability, showing comparable performance when using parametric K1 perfusion maps and VOI-based analysis. For longitudinal evaluation, changes above 30% are likely to represent actual changes in tumour perfusion, for example as response to a specific treatment.

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment MRI in cancer diagnosis Prostate Cancer Treatment and Research

Publication details

Journal / source
EJNMMI Research
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Pages
23–23
Publication date
8 January 2026
Language
EN